Targeted therapeutic strategy for MyC-associated diffuse large B cell lymphomas
10.3781/j.issn.1000-7431.2017.55.190
- Author:
Lingzhe KONG
1
Author Information
1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer
- Publication Type:Journal Article
- Keywords:
Diffuse;
Large B-cell;
Lymphoma;
Myc;
Targeted therapy
- From:
Tumor
2017;37(8):895-900
- CountryChina
- Language:Chinese
-
Abstract:
Myc behaves as a central transcriptional factor, regulating cell proliferation, cell cycle progression, apoptosis, differentiation, metabolism and other functions. In diffuse large B cell lymphomas (DLBCL), Myc abnormality has been identified as an independent prognostic marker. Myc-associated DLBCL tends to have more aggressive phenotypes, lower sensitivity to standard chemotherapeutic regimens, and worse outcomes compared with other types of DLBCL. Myc per se has generally been deemed undruggable, and the pharmacological attempts to directly inhibit Myc have not borne fruits. However, with the understanding of biological functions of Myc, a series of small molecular inhibitors targeting Myc transcription and protein regulation have been developed. The potential antagonistic strategies for Myc mainly include interfering with its stability, decreasing its expression, and acting on the downstream target genes. This review discusses the therapeutic targets for Myc-related DLBCL, with an emphasis on their mechanisms and advances, in the hope to improve the outcomes of these patients.
